Johnson & Johnson wins EU approval to buy Actelion
Credit: iStock.com/pattonmania
The European Commission’s Directorate-General for Competition has conditionally cleared pharmaceutical company Johnson & Johnson’s acquisition of Swiss biotechnology company Actelion after a Phase I review, subject to conditions aimed at maintaining competition in the development of insomnia drugs.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Subscribe now